A carregar...
Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer
BACKGROUND. Among women with surgically removed, high-risk HER-2/neu-positive breast cancer, trastuzumab has demonstrated significant improvements in disease-free and overall survival. The objective of this study is to evaluate the cost-effectiveness of the currently recommended 12-month adjuvant pr...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3286164/ https://ncbi.nlm.nih.gov/pubmed/22302231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0379 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|